

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EDDING GENOR GROUP HOLDINGS LIMITED

亿腾嘉和醫藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6998)

VOLUNTARY ANNOUNCEMENT LATEST UPDATE ON COOPERATION WITH NANOPEPTIDE

This announcement is made by Edding Genor Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Group about the latest business advancement of the Group. Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the circular of the Company dated 5 December 2025 (the “**Circular**”).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company hereby announces that on 3 March 2026, the Group entered into a supplemental agreement and a termination agreement (collectively, the “**Agreements**”) with Nanopeptide (Qingdao) Biotechnology Ltd. (納肽得(青島)生物醫藥有限公司) (“**Nanopeptide**”).

Reference is made to the section headed “Business of the Target Group” in the Circular in relation to, among other things, the in-licensing arrangements entered into between the Target Group and Nanopeptide in respect of certain siRNA assets. In September 2023, the Target Group entered into an in-licensing agreement with Nanopeptide to obtain the exclusive rights to develop, manufacture and commercialise two novel pre-clinical siRNA assets, and further in-licensed another siRNA asset in May 2024.

Pursuant to the Agreements, the parties agreed to adjust the cooperation arrangements as follows: (i) the territorial scope of one siRNA asset – angiotensin-like protein 3 (“**ANGPTL3**”) has been expanded from the original agreed territories to worldwide, under which the Group will obtain the global patent rights relating to the ANGPTL3 molecule and will jointly own the GalNAc platform technology with Nanopeptide; and (ii) the cooperation arrangements in relation to the other two pre-clinical siRNA assets have been terminated.

Upon execution of the supplemental agreement, the licensed territory of the siRNA asset targeting ANGPTL3 has been expanded to a global scope, thereby further enhancing the value of the asset to the Company and contributing to the enhancement of the Company's long-term shareholder value. The Company's EDP167, a drug candidate targets ANGPTL3, has successfully completed the first subject dosing in its phase II clinical trial. For further details of EDP167, please refer to the Company's announcement dated 9 February 2026.

Taking into account the competitive market environment, the Company terminated the cooperation arrangements in relation to the other two pre-clinical siRNA assets. As the other two siRNA assets remain at an early stage of research and development, the termination of the cooperation arrangements in respect of such assets will not have any material adverse impact on the business, financial condition or operations of the Group.

By Order of the Board
Edding Genor Group Holdings Limited
Mr. Ni Xin
Chairman and Executive Director

Hong Kong, 3 March 2026

As of the date of this announcement, the Board comprises Mr. Ni Xin and Ms. Zhai Jing as executive Directors; Dr. David Guowei Wang and Mr. Yu Tieming as non-executive Directors; and Dr. Xu Qing, Mr. Chen Wen and Ms. Zheng Jingjing as independent non-executive Directors.